CVB Financial Corp. enters the week with a rare combination: a fresh analyst upgrade landing on the same day short sellers have meaningfully rebuilt positions over the past month.
Raymond James moved to Outperform on Tuesday, the first upgrade the stock has seen in recent memory, with analyst Michael Rose setting a $25 target. That call lands with the stock at $22.55 — up 4.6% on the week and 10.8% over the past month — implying roughly 11% further upside from current levels. The Street is not uniformly bullish. Stephens reiterated Equal-Weight at $23 in mid-June, effectively a hold at current prices. Piper Sandler maintains Overweight with a $27 target, the most constructive print on the board. The mean target of $24 sits just above the current price, suggesting the consensus sees limited near-term room to run even after the recent rally. The bull case rests on expanding net interest margins and raised EPS guidance for 2025-2026. Bears point to a 9% sequential decline in core noninterest income and ongoing pricing pressure in loans and deposits that threatens to compress margins back.
Short positioning has shifted sharply in the background. Short interest has climbed 33% over the past month to 6.6% of the free float — a level that crosses the threshold where it becomes a genuine story, not a footnote. The one-week move was a 14% jump in shares short, the most aggressive acceleration in the 30-day window. That said, the borrow market tells a different story: cost to borrow is running at just 0.43%, down 23% on the week, a very low rate that signals no friction for shorts entering or exiting positions. Availability is exceptionally loose at 1,211% — meaning there are roughly twelve shares available to lend for every one already borrowed. That combination of rising short interest and cheap, plentiful borrow suggests this is a considered fundamental bet by shorts, not a panic or a squeeze setup.
Options positioning has swung decisively to the bullish side. The put/call ratio has dropped to 0.29, near the 52-week low of 0.20, and well below the 20-day average of 2.51. The z-score of -0.57 is not extreme, but the direction is unambiguous: after a period in May when the PCR was running above 10 — heavily skewed toward puts — the past two weeks have seen a near-complete reversal toward calls. That flip coincides almost exactly with the stock's re-rating higher from the $19-$20 range in mid-May.
The insider data reinforces that directional read. Vice Chairman George Borba purchased just under $2 million in shares across four tranches in May, buying consistently between $19.85 and $20.45. Those buys came just ahead of the rally and represent the most concentrated insider buying the stock has seen in the recent data window. Two smaller executive sells — General Counsel and Chief Risk Officer — totalling under $410,000 combined in early June look routine against Borba's commitment. Net insider buying over 90 days comes to roughly $4.1 million, a constructive signal for a stock of this size.
Valuation is undemanding. The P/E stands near 11.7x and price-to-book is just above 1.1x — both in line with or below typical regional bank multiples. The 12-month forward EPS growth factor ranks in the 70th percentile. EPS momentum over 30 days also screens positively at the 65th percentile. Against peers, BUSE and MBWM both gained around 2-5% on the week, broadly in line with CVBF's move, suggesting the rally is partly a sector tailwind rather than a CVBF-specific re-rating story.
Q2 earnings land on July 24. The last two prints produced muted reactions — a +2.5% one-day move in May 2026 and a -1.5% move in April. The question heading into that date is whether the margin expansion narrative can deliver a cleaner beat, or whether the noninterest income pressure that bears are focused on reasserts itself.
See the live data behind this article on ORTEX.
Open CVBF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
